OnCo
ideasIdea

A swallowable sponge test for reflux patients, offered in pharmacies

A pill on a string collects cells from the food pipe and finds Barrett's oesophagus, a precursor of cancer. Offering it in pharmacies to people on long-term heartburn drugs would find it early.

The capsule sponge (Cytosponge-TFF3) increased Barrett's detection ten-fold in primary care in BEST3; BEST4 tests screening and surveillance. Propose delivery through community pharmacies for patients on chronic acid suppression, with nurse-administered sponge, a central laboratory, and AI-assisted pathology.

Hypothesis
Pharmacy-based capsule sponge screening achieves at least 40% uptake in eligible reflux patients and detects dysplastic Barrett's at three times the rate of usual care, reducing stage III-IV oesophageal adenocarcinoma at five years.
Rationale
Precursor detection plus endoscopic ablation is curative; the bottleneck is reaching the population, not the test.
What would test it
Cluster-randomised pharmacy pilot in one region (50 pharmacies).
Maturity
being tested at scale
Who has to act
clinic
Cost to try
Medium ($1M to $50M)
Years to first evidence
5
Bottlenecks it attacks

Connected

5top